Ibnsina Pharma reported audited earnings results for the first quarter March 31, 2018. For the quarter ending 31 March 2018, posting net revenues of EGP 2.9 billion, up 51.1% year-on-year. EBITDA recorded an impressive 69.4% year-on-year increase to EGP 92.3 million in first quarter of 2018 with a slight expansion in its margin of 0.3 percentage points. Net profit came in at EGP 28.0 million in first quarter of 2018, representing a year-on-year growth of 46.3%. Total CAPEX amounted to EGP 45.0 million in first quarter of 2018, directed at investments in new distribution sites as well as upgrades to existing ones.

For the year 2018, the company expects CapEx to be EGP 170 million.